GlassScriptPhysician profile
Samuel O Bada
NPI 1770530586
$1,775.08
in general payments reported to CMS, 2019-2025
24 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $370 · 2021: $287 · 2022: $272 · 2023: $62.59 · 2024: $189 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $405.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $225.83 | 2019-2022 | |
| Pfizer INC. | $197.34 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $178.48 | 2022-2025 | Farxiga |
| Novo Nordisk INC | $173.12 | 2020-2021 | |
| Dexcom, INC. | $92.94 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $80.29 | 2022-2025 | Uzedy |
| Abbvie INC. | $75.61 | 2022-2023 | Vraylar |
| Allergan, INC. | $51.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.38 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.41 | 2024-2025 | Jardiance, Synjardy |
| Neurocrine Biosciences, INC. | $20.18 | 2022 | |
| Cmp Pharma, INC. | $19.88 | 2021 | |
| Viatris Specialty LLC | $19.15 | 2025 | Yupelri |
| Amgen INC. | $18.29 | 2025 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $17.70 | 2025 | Hyalgan |
| Nevro Corp. | $16.61 | 2023 | Senza |
| Otsuka America Pharmaceutical, INC. | $16.46 | 2022 | |
| Biogen, INC. | $15.79 | 2021 | |
| Corcept Therapeutics | $15.48 | 2019 | |
| Inogen, INC. | $13.57 | 2022 | |
| Lilly USA, LLC | $13.53 | 2025 | Jardiance |
| Mylan Specialty L.P. | $13.04 | 2019 | |
| Astellas Pharma US INC | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Bada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.